Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epacadostat + Pembrolizumab in Advanced Solid Tumors
NCT02178722Phase 2Completed
- Sponsor
- Incyte
- Start
- Jul 2014
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of epacadostat in melanoma, non-small cell lung cancer (NSCLC), urothelial carcinoma (UC) and 8 more (2 arms), sponsored by Incyte. Primary endpoints: Treatment-Emergent Adverse Events at 54 months and Objective Response Rate at 54 months. Started Jul 2014; status: completed.
02
Drugs
epacadostat
03
Conditions
melanomanon-small cell lung cancer (NSCLC)urothelial carcinoma (UC)renal cell carcinoma (RCC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02178722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02178722.